Drug Formulary Review articles from March 2008

Drug Formulary Review archives from March 2008

Transitioning patients from clinic to physician-managed care didn't work.
March 1, 2008... Transitioning patients from clinic to physician-managed care didn't work Significant decrease in control after transition to physician What do you do when your successful hospital-based anticoagulation clinic has more patients than...

CDIX program makes alerts more meaningful.
March 1, 2008... CDIX program makes alerts more meaningful Alerts limited to those deemed critical Electronic drug interaction alerts can be useful in preventing harmful drug-drug interactions, but too many clinically insignificant alerts can lead to...

Caution when starting statins in high-risk patients.
March 1, 2008... Caution when starting statins in high-risk patients Effects on cerebrovascular disease not clear Research at the University of Mississippi Medical Center indicating that statin therapy reduces risk of developing all cerebrovascular...

Drug safety lapses at Cedars-Sinai.
March 1, 2008... Drug safety lapses at Cedars-Sinai State investigation confirms internal findings The California Department of Public Health says Los Angeles' Cedars-Sinai Medical Center's handling of high-risk drugs placed its pediatric patients in...

News Briefs.
March 1, 2008... Quick test for MRSA infections OK'd FDA cleared for marketing BD Diagnostics' GeneOhm™ StaphSR assay that uses molecular methods to determine whether a blood sample contains Staphylococcus aureus bacterium. It's the first rapid blood...

Drug Criteria & Outcomes: The dangerous fight against plaque: The use of natalizumab in the treatment of multiple sclerosis.
March 1, 2008... Drug Criteria & Outcomes The dangerous fight against plaque: The use of natalizumab in the treatment of multiple sclerosis By Alison R. McGriff, PharmD Candidate McWhorter School of Pharmacy, Samford University, Homewood, AL A...

Drug Criteria & Outcomes: New FDA Approvals.
March 1, 2008... Drug Criteria & Outcomes FDA recently announced these approvals: Biogen Idec's Tysabri® (natalizumab) has been approved by FDA for treating moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an...

CE objectives/questions.(continuing education)(Brief article)
March 1, 2008... CE objectives/questions This CE program will improve participants' ability to: *Compare the clinical efficacy and safety of one therapeutic agent over another used in the same setting. *Assess clinical trial data and explain how...